AI-driven biotherapeutic research and technology company ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) announced on Monday that it has contributed to a pivotal Mayo Clinic-led study on mitochondrial health, recently published in Autophagy, which explores aging-related mitochondrial dysfunction linked to neurodegenerative diseases such as Parkinson's and Alzheimer's.

Through its proprietary Rabbit B Cell Select platform, IPA generated antibodies targeting phosphorylated ubiquitin (p-S65-Ub), a key marker of mitochondrial damage, enabling precise detection of age-related cellular deterioration.

With the anti-aging market forecasted to reach USD81bn by 2028, IPA is well-positioned to capitalise on this growth. Its collaboration with Mayo Clinic underscores IPA's role in advancing age-related research, while its subsidiary, Talem Therapeutics, bolsters its internal pipeline of next-generation therapeutic antibodies.

This dual strategy reinforces IPA's potential in the longevity sector, presenting significant opportunities for market expansion and shareholder value.